NAGE 250516 7.50C(NAGE250516C7500) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

NAGE250516C7500

Watchlist

0.85
+0.10+13.33%

15min DelayClose Apr 29 16:00 ET

0.85High0.74Low

Intraday

5D
Daily

News

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
BusinesswireApr 29 08:32 ET
Express News | Niagen Bioscience Welcomes DR. Pinchas Cohen to Scientific Advisory Board
ReutersApr 29 08:32 ET
Press Release: Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
Dow JonesApr 28 08:36 ET
Roth MKM Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $8
Moomoo NewsApr 8 03:33 ET · Ratings
Sector Update: Health Care Stocks Slipping in Afternoon Trading
MT NewswiresApr 7 14:05 ET
Niagen Says Its Operations Remain Resilient Amid Recent Tariff Developments
MT NewswiresApr 7 09:59 ET

Comments

$ChromaDex (CDXC.US)$
this is $Niagen Bioscience (NAGE.US)$ now

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

$Niagen Bioscience (NAGE.US)$
Game-Changing Patent Win: Niagen Locks Down Exclusive Rights to Critical NR Technology

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

$Niagen Bioscience (NAGE.US)$ Niagen Bioscience Secures US Patent For Composition Of Matter For Nicotinamide Riboside Salt Forms
Benzinga· 2mins ago

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

$Niagen Bioscience (NAGE.US)$
ChromaDex Transforms to Niagen Bioscience as NAD+ Leader Reports Record $99.6M Revenue

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

Read more